Based on neuroimaging techniques and cerebrospinal fluid (CSF) analysis, AD pathology biomarkers, such as Aβ deposition in the brain, Aβ42 and pathologic tau level in CSF, have been added to clinical criteria. Here, MAPT is linked to Alzheimer disease.